

Restructuring the ATC L-Class: Antineoplastics and Immunomodulating Agents

Enhancing the classification structure for improved categorization

ephmra
excellence - community - standards

Today’s Webinar Agenda

- Challenges in the Current ATC L-Class
- Proposed Changes
- Revised Classification Structure in Detail
- Benefits of Restructuring
- Impact of Revised Classification Structure
- Stakeholder Engagement and Support
- Implementation Timeline
- Q&A

ephmra
excellence - community - standards



Challenges in the Current ATC L-Class

ephmra
excellence - community - standards

Limitations of Combining Antineoplastic and Immunomodulating Agents

Combined Drug Classification

- The ATC L-Class currently groups antineoplastic and immunomodulating agents together

Challenges with Emerging Therapies

- New therapies have necessitated the introduction of new classes
- This has resulted in space issues in the current classification structure

ephmra
excellence - community - standards

Current L-Class Structure

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L1: ANTINEOPLASTICS

- L1A: ALKYLATING AGENTS
- L1B: ANTIMETABOLITES
- L1C: PLANT-BASED ANTINEOPLASTICS
- L1D: ANTINEOPLASTIC ANTIBIOTICS
- L1F: PLATINUM ANTINEOPLASTICS
- L1G: MONOCLONAL ANTIBODY ANTINEOPLASTICS
- L1H: PROTEIN KINASE INHIBITOR ANTINEOPLASTICS
- L1J: PROTEASOME INHIBITOR ANTINEOPLASTICS
- L1K: LIDOMIDE ANTINEOPLASTICS
- L1L: PARP INHIBITOR ANTINEOPLASTICS
- L1X: ALL OTHER ANTINEOPLASTICS

L2: CYTOSTATIC HORMONE THERAPY

- L2A: CYTOSTATIC HORMONES
- L2B: CYTOSTATIC HORMONE ANTAGONISTS

L3: IMMUNOSTIMULATING AGENTS

- L3A: IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS
- L3B: INTERFERONS

L4: IMMUNOSUPPRESSANTS

- L4A: ANTI-TNF PRODUCTS
- L4B: INTERLEUKIN INHIBITORS
- L4C: JAK INHIBITORS
- L4D: OTHER IMMUNOSUPPRESSANTS

Current Protein Kinase Inhibitor Structure Has Little Space for Future Growth

L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L1	**ANTINEOPLASTICS**
L1H	**PROTEIN KINASE INHIBITOR ANTINEOPLASTICS**
L1H1	Protein kinase inhibitor antineoplastics, BCR-ABL
L1H2	Protein kinase inhibitor antineoplastics, EGFR
L1H3	Protein kinase inhibitor antineoplastics, ALK
L1H4	Protein kinase inhibitor antineoplastics, BRAF/MEK
L1H5	Protein kinase inhibitor antineoplastics, CDK 4/6
L1H6	Protein kinase inhibitor antineoplastics, BTK
L1H7	Protein kinase inhibitor antineoplastics, JAK
L1H9	Protein kinase inhibitor antineoplastics, other



Proposed Changes to the ATC L-Class Structure

ephmra
excellence - community - standards

Key Changes

New ATC1 for Immunological Products

- A dedicated 1ST level ATC established exclusively for immunological products

Promotion of antineoplastic classes from 3rd level to 2nd level

- This will future-proof the classification, allowing for innovation and emerging therapies

ephmra
excellence - community - standards



Proposed L-Class and F-Class Structure

L: ANTINEOPLASTICS

- L5: ALKYLATING ANTINEOPLASTICS
- L6: ANTIMETABOLITE ANTINEOPLASTICS
- L7: PLANT-BASED ANTINEOPLASTICS
- L8: ANTIBIOTIC ANTINEOPLASTICS
- L9: PLATINUM ANTINEOPLASTICS
- L10: MONOCLONAL ANTIBODY ANTINEOPLASTICS
- L11: PROTEIN KINASE INHIBITOR ANTINEOPLASTICS
- L12: PROTEASOME INHIBITOR ANTINEOPLASTICS
- L13: LIDOMIDE ANTINEOPLASTICS
- L14: PARP INHIBITOR ANTINEOPLASTICS
- L15: ANTINEOPLASTICS, OTHER
- L2: CYTOSTATIC HORMONE THERAPY
  - L2A: CYTOSTATIC HORMONES
  - L2B: CYTOSTATIC HORMONE ANTAGONISTS

F: IMMUNOMODULATORS

- F1: IMMUNOSTIMULATING AGENTS
  - F1A: IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS
  - F1B: INTERFERONS
- F2: IMMUNOSUPPRESSANTS
  - F2A: ANTI-TNF PRODUCTS
  - F2B: INTERLEUKIN INHIBITORS
  - F2C: JAK INHIBITORS
  - F2X: IMMUNOSUPPRESSANTS, OTHER
- F9: IMMUNOMODULATORS, OTHER

ephmra
excellence - community - standards

Proposed Protein Kinase Inhibitor Structure Allows for Approval of Novel Targeted Agents

L	ANTINEOPLASTICS
L11	**PROTEIN KINASE INHIBITOR ANTINEOPLASTICS**
L11A	Protein kinase inhibitor antineoplastics, BCR-ABL
L11B	Protein kinase inhibitor antineoplastics, EGFR
L11C	Protein kinase inhibitor antineoplastics, ALK
L11D	Protein kinase inhibitor antineoplastics, BRAF/MEK
L11E	Protein kinase inhibitor antineoplastics, CDK 4/6
L11F	Protein kinase inhibitor antineoplastics, BTK
L11G	Protein kinase inhibitor antineoplastics, JAK
L11X	Protein kinase inhibitor antineoplastics, other



Benefits of the ATC L-Class Restructuring

ephmra
excellence - community - standards

Future-Proofing the Classification System

Improved Clarity

- By giving oncology and immunology their own first level classes

Adaptability to Future

- By creating space so the classification can continue to adapt to future developments for many years to come

ephmra
excellence - community - standards



Impacts of the ATC L-Class Restructuring

ephmra
excellence - community - standards

Impacts of the Revised Classification Structure

Sales Ranking Changes

Based on IQVIA Q2/2025 data

Current ATC1	% Share
L: Antineoplastics and Immunomodulating Agents	**26%**
A: Alimentary Tract and Metabolism	19%
N: Nervous System	10%
J: General Systemic Antiinfectives	9%

Future ATC1	% Share
A: Alimentary Tract and Metabolism	19%
L: Antineoplastics	**15%**
N: Nervous System	10%
F: Immunomodulators	**10%**

Practical Considerations

- Internal systems, processes and analyses will need to be updated to accommodate this change

ephmra
excellence - community - standards



Stakeholder Engagement and Implementation Timeline

ephmra
excellence - community - standards

Stakeholder Feedback and Available Resources

Encouraging Feedback

- Organizations, especially oncology teams, are encouraged to review proposals and provide meaningful feedback

Resources

- Webinar
- News articles and LinkedIn posts
- Available on the EPHMRA website

Any questions or feedback, please contact:

Bernadette Rogers (generalmanager@ephmra.org)

ephmra
excellence - community - standards

Key Dates for Voting and Implementation

Voting Schedule

- A vote by EPHMRA members to approve these changes is scheduled for May/June of 2026

Implementation Date

- Upon approval, the new structure will be implemented starting January 2027 when all products will be moved to their new classifications

ephmra
excellence - community - standards



Q&A

ephmra

excellence - community - standards